A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Inclusion Criteria:

• Has a histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL).

• Has radiographically measurable DLBCL per the Lugano Response Criteria, as assessedlocally by the investigator.

• Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 within 7 days prior to study treatment initiation.

• Has adequate organ function.

• Is able to provide new or archival tumor tissue sample not previously irradiated.

Zilovertamab vedotin plus R-GemOx, or R-GemOx study arms:

• Has relapsed or refractory DLBCL and is ineligible for or have failed autologousstem-cell transplant (ASCT) and have failed at least 1 line of prior therapy.

• Has post-chimeric antigen receptor T (post-CAR-T) cell therapy failure or isineligible for CAR-T cell therapy.

Not applicable with protocol amendment 4: Zilovertamab vedotin plus Bendamustine Rituximab (BR), and Bendamustine Rituximab study arms:

• Has relapsed or refractory DLBCL and is ineligible for or have failed ASCT and havefailed at least 2 lines of prior therapy.

• Has post-CAR-T therapy failure or is ineligible for CAR-T cell therapy.

Exclusion Criteria:

• Not applicable with protocol amendment 4: Has history of transformation of indolentdisease to DLBCL

• Has received solid organ transplant at any time.

• Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL).

• Has clinically significant (ie, active) cardiovascular disease or serious cardiacarrhythmia requiring medication.

• Has ongoing graft-versus-host disease (GVHD) of any grade, or is receiving treatmentfor their GVHD.

• Has clinically significant pericardial or pleural effusion.

• Has ongoing Grade >1 peripheral neuropathy.

• Has a history of a second malignancy, unless potentially curative treatment has beencompleted with no evidence of malignancy for 2 years.

• Has a demyelinating form of Charcot-Marie-Tooth disease.

• Has contraindication to any of the study intervention components including but notlimited to prior anaphylactic reaction.

• Has received prior systemic anticancer therapy, including investigational agentswithin 4 weeks prior to the first dose of study intervention.

• Has received prior radiotherapy within 4 weeks of start of study intervention.Participants must have recovered from all radiation-related toxicities, not requirecorticosteroids, and not have had radiation pneumonitis.

• Has ongoing corticosteroid therapy.

• Has received a live or live-attenuated vaccine within 30 days before the first doseof study intervention.

• Is currently participating in or has participated in a study of an investigationalagent or has used an investigational device within 4 weeks before the first dose ofstudy intervention.

• Has known active central nervous system (CNS) lymphoma involvement or active CNSinvolvement by lymphoma. Participants with prior CNS involvement are eligible iftheir CNS disease is in radiographic, cytological (for cerebrospinal fluid disease),and clinical remission.

• Has an active infection requiring systemic therapy.

• Has a known history of human immunodeficiency virus (HIV) infection.

• Has a known active Hepatitis C virus infection.

• Has a known psychiatric or substance abuse disorder that would interfere with theparticipant's ability to cooperate with the requirements of the study.